|
rs28934574
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs28934575
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Fifty-five out of 311 gliomas had IDH R132H mutations (9/16 DAs; 8/48 AAs; 3/211 GBMs; 35/36 oligodendrogliomas), one DA, and one oligodendroglioma had other IDH mutations.
|
31758617 |
2020 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The histopathologic examination confirmed a leptomeningeal spread of a K27M-mutated anaplastic astrocytoma (WHO° III) without R132H-IDH1 mutation.
|
29066318 |
2018 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study looks into the potential prognostic use of mitotic activity and the proliferation markers Ki67/MiB-1 (Ki67), survivin and DNA topoisomerase IIα (TIIα) in 59 WHO grade II diffuse astrocytomas (DA) and 33 WHO grade III anaplastic astrocytomas (AA), IDH1 R132H-mutated and not otherwise specified (NOS) by means of immunohistochemistry.
|
28214203 |
2017 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3).
|
28851427 |
2017 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe a patient who underwent surgical resection, followed by adjuvant radiation and temozolomide of a World Health Organization (WHO) III anaplastic astrocytoma in the right temporal lobe, exhibiting an IDH1 (R132H) mutation.
|
26911558 |
2016 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
R132H was the only mutation found in 17.6% (6/34) of cases, including in astrocytomas, anaplastic astrocytomas, oligodendroglioma, and anaplastic oligoastrocytoma.
|
26125858 |
2015 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We show that expression levels of many proteins are altered in IDH1(R132H) mutant anaplastic astrocytoma.
|
24473683 |
2014 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The IDH1 c.G395A; p.R132H mutation was observed in 56 and 94 % of grade II and grade III astrocytoma cases, respectively.
|
23934769 |
2014 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the anti-IDH1-R132H-specific monoclonal antibody IMab-1 is very useful for detecting IDH1-R132H in immunohistochemistry, and predicting the time to progression in grade III anaplastic astrocytomas.
|
21344322 |
2011 |
|
rs118101777
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Fifty-five out of 311 gliomas had IDH R132H mutations (9/16 DAs; 8/48 AAs; 3/211 GBMs; 35/36 oligodendrogliomas), one DA, and one oligodendroglioma had other IDH mutations.
|
31758617 |
2020 |
|
rs118101777
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3).
|
28851427 |
2017 |
|
rs118101777
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We describe a patient who underwent surgical resection, followed by adjuvant radiation and temozolomide of a World Health Organization (WHO) III anaplastic astrocytoma in the right temporal lobe, exhibiting an IDH1 (R132H) mutation.
|
26911558 |
2016 |
|
rs118101777
|
|
|
0.040 |
GeneticVariation |
BEFREE |
R132H was the only mutation found in 17.6% (6/34) of cases, including in astrocytomas, anaplastic astrocytomas, oligodendroglioma, and anaplastic oligoastrocytoma.
|
26125858 |
2015 |
|
rs55819519
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
rs55819519
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
|
rs1415342243
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
rs760090729
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
rs866960721
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
rs751859698
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Missense mutations in the MSH4 DNA repair gene (c.2480T>A; p.I827N) were detected in three patients with gliomas (two anaplastic astrocytomas, two glioblastomas).
|
25041856 |
2014 |
|
rs1057519903
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The K27M mutation occurred in 35 of 129 glioblastomas (27.1%) and in 5 of 28 (17.9%) anaplastic astrocytomas.
|
23429371 |
2013 |
|
rs1412829
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wrensch and colleagues provided further evidence to 2 risk loci (CDKN2B rs1412829 and RTEL1 rs6010620) for GBM and anaplastic astrocytoma.
|
20212223 |
2010 |